Your Article Summary
See Latest ArticlesABT-751, a novel tubulin-binding agent, decreases tumor perfusion and disrupts tumor vasculature
Anti-Cancer Drugs, 07/02/09
Luo Y et al. - The results show that ABT-751 is a tubulin-binding agent with antivascular properties. Microtubule disruption and morphological changes in vascular endothelial cells may be responsible, at least in part, for the dysfunction of tumor blood vessels after ABT-751 treatment.
Related Articles
Triple-negative breast cancer—current status and future directions
Annals of Oncology, 11/16/09
Relevance Score: 45%
Use of remifentanil as a sedative agent in critically ill adult patients: a meta-analysis
Anaesthesia, 11/11/09
Relevance Score: 45%
Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond
Heart Failure Reviews, 11/03/09
Relevance Score: 45%
The Impact of Bittering Agents on Pediatric Ingestions of Antifreeze
Clinical Pediatrics, 10/26/09
Relevance Score: 45%
The role of urate and xanthine oxidase in vascular oxidative stress: future directions
Therapeutics and Clinical Risk Management, 10/07/09
Relevance Score: 45%
Today in Basic Science/Genetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia
Haematologica, 12/20/09
The mitogen-activated protein kinase signaling pathways: role in megakaryocyte differentiation
Journal of Thrombosis and Haemostasis, 12/20/09
Reprogramming T Lymphocytes for Melanoma Adoptive Immunotherapy by T-Cell Receptor Gene Transfer with Lentiviral Vectors
Cancer Research, 12/20/09